Asenapine vs Perseris
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Asenapine
Marketed by AbbVie and partners
NCT00212784 · Phase 3 · completed
This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.
Reported efficacy
Change in total PANSS score at endpoint (Screening, Week 76, 100, and once every 24 weeks thereafter until endpoint): Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint (unclear)
Result source: NCT00212771
Perseris
Rights held by Indivior Pharmaceuticals, Inc.; US product discontinued
NCT02109562 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 354 participants and a clinical primary endpoint measuring change in PANSS total score. The primary endpoint was met for both RBP-7000 doses: PANSS scores improved significantly more than with placebo.
Reported efficacy
Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): RBP-7000 90 mg -15.367 units on a scale (Standard Error 1.223) | RBP-7000 120 mg -16.456 units on a scale (Standard Error 1.2073) vs Placebo -9.219 units on a scale (Standard Error 1.2162) (met)
Result source: NCT02109562
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Asenapine | Perseris |
|---|---|---|
| PANSS total, change | -25.5 vs -17.8−7.7 vs placeboNCT0119025418 other results
| -16.5 vs -9.2−7.2 vs placeboNCT021095627 other results
|
| CGI-S, change | -1.3 vs -0.8−0.5 vs placeboNCT0119025417 other results
| 0 vs -0.3+0.3 vs placeboNCT022038387 other results
|
| PANSS response | 39.3% vs 20.7%+18.6 vs placeboNCT010981101 other result
| —Not reported |
| PSP, change | —Not posted · NCT00212771 | —Not reported |
| Relapse (% of patients) | —Not posted · NCT00212771 | —Not reported |
PANSS total, change
- Asenapine
- -25.5 vs -17.8−7.7 vs placeboNCT01190254
18 other results
- -21.7 vs -16.2 NCT01617187
- -12.2 vs -0.9 NCT01098110
- -14.2 vs -0.9 NCT01098110
- -23.7 vs -17.8 NCT01190254
- -17.4 vs -16.2 NCT01617187
- -19 vs -15.4 NCT01617187
- -17.1 vs -15.5 NCT01617187
- -14.8 vs -13.2 NCT01617187
- -12.5 vs -10.7 NCT01617187
- -9.1 vs -7.1 NCT01617187
- -4.9 vs -4.8 NCT01617187
- -17 vs -15.4 NCT01617187
- -12.3 vs -15.5 NCT01617187
- -12 vs -13.2 NCT01617187
- -9.9 vs -10.7 NCT01617187
- -7.2 vs -7.1 NCT01617187
- -4 vs -4.8 NCT01617187
- -21 vs -27.5 NCT00212784
- Perseris
- -16.5 vs -9.2−7.2 vs placeboNCT02109562
7 other results
- -15.4 vs -9.2 NCT02109562
- -1.2 vs -4.8 NCT02203838
- -1.2 vs -8.2 NCT02203838
- -2.4 vs -4.8 NCT02203838
- -9.4 vs -8.2 NCT02203838
- -8.3 vs -4.8 NCT02203838
- -10 vs -8.2 NCT02203838
CGI-S, change
- Asenapine
- -1.3 vs -0.8−0.5 vs placeboNCT01190254
17 other results
- -1.2 vs -1 NCT01617187
- -0.7 vs -0.2 NCT01098110
- -1.1 vs -0.8 NCT01617187
- -0.9 vs -0.8 NCT01617187
- -0.8 vs -0.7 NCT01617187
- -0.6 vs -0.5 NCT01617187
- -0.3 vs -0.3 NCT01617187
- -0.2 vs -0.2 NCT01617187
- -0.8 vs -0.2 NCT01098110
- -1.1 vs -0.8 NCT01190254
- -0.9 vs -1 NCT01617187
- -0.9 vs -0.8 NCT01617187
- -0.7 vs -0.8 NCT01617187
- -0.6 vs -0.7 NCT01617187
- -0.6 vs -0.5 NCT01617187
- -0.3 vs -0.3 NCT01617187
- -0.1 vs -0.2 NCT01617187
- Perseris
- 0 vs -0.3+0.3 vs placeboNCT02203838
7 other results
- -0.1 vs -0.3 NCT02203838
- -0.9 vs -0.5 NCT02109562
- -0.9 vs -0.5 NCT02109562
- -0.1 vs -0.3 NCT02203838
- -0.4 vs -0.3 NCT02203838
- -0.2 vs -0.3 NCT02203838
- -0.3 vs -0.3 NCT02203838
PANSS response
- Asenapine
- 39.3% vs 20.7%+18.6 vs placeboNCT01098110
1 other result
- 43.8% vs 20.7% NCT01098110
- Perseris
- —Not reported
PSP, change
- Asenapine
- —Not posted · NCT00212771
- Perseris
- —Not reported
Relapse (% of patients)
- Asenapine
- —Not posted · NCT00212771
- Perseris
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Asenapine: 4 of 4 rows · Perseris: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Asenapine | Perseris |
|---|---|---|
| Dropout rate | 44.4%5 mg twice dailya NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results16.7%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 54.8%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 0%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 1%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 49.7% NCT01244828 · Phase 3 · registry result, not featured evidence 35.2%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 40.1%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 50%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 20.9%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 20.8%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 17.3%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 33.7% NCT00174265 · Phase 3 · registry result, not featured evidence 50.4% NCT00145496 · Phase 3 · registry result, not featured evidence 30.4% NCT00150176 · Phase 3 · registry result, not featured evidence 15.7% NCT00265343 · Phase 3 · registry result, not featured evidence 67.7% NCT00156065 · Phase 3 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence 33.3%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 25%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 28.6%120 mgb NCT02109562 · Phase 3 · combination show 8 more results22.4%90 mg NCT02109562 · Phase 3 · combination 54.5%120 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 51.6%90 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 51.5%De Novo Participants NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 78.3%180 mg subcutaneous NCT03978832 · Phase 4 · registry result, not featured evidence 40%120 mg NCT01677377 · Phase 2 · registry result, not featured evidence 6.7%90 mg NCT01677377 · Phase 2 · registry result, not featured evidence 6.7%60 mg NCT01677377 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 22.2%5 mg twice dailya NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results0%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 22.3%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 0%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 0%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 23.6% NCT01244828 · Phase 3 · registry result, not featured evidence 17%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 17.6%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 0%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 5.1%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 7.5%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 6.1%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 8.1% NCT00174265 · Phase 3 · registry result, not featured evidence 17.2% NCT00145496 · Phase 3 · registry result, not featured evidence 8.2% NCT00150176 · Phase 3 · registry result, not featured evidence 7.5% NCT00265343 · Phase 3 · registry result, not featured evidence 11.8% NCT00156065 · Phase 3 · registry result, not featured evidence —5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 1.7%120 mgb NCT02109562 · Phase 3 · combination show 8 more results0%90 mg NCT02109562 · Phase 3 · combination 6.1%120 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 9.7%90 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 11.3%De Novo Participants NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 1.4%180 mg subcutaneous NCT03978832 · Phase 4 · registry result, not featured evidence —120 mg NCT01677377 · Phase 2 · registry result, not featured evidence —90 mg NCT01677377 · Phase 2 · registry result, not featured evidence —60 mg NCT01677377 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%5 mg twice dailya NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results0%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 20.4%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 4.4%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 5.2%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 8.9% NCT01244828 · Phase 3 · registry result, not featured evidence 5.7%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 2.8%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 12.5%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 3.6%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 2.8%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 3.1%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 4.7% NCT00174265 · Phase 3 · registry result, not featured evidence 12.3% NCT00145496 · Phase 3 · registry result, not featured evidence 3.1% NCT00150176 · Phase 3 · registry result, not featured evidence 6.7% NCT00265343 · Phase 3 · registry result, not featured evidence 14.1% NCT00156065 · Phase 3 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 0.9%120 mgb NCT02109562 · Phase 3 · combination show 8 more results0%90 mg NCT02109562 · Phase 3 · combination 9.1%120 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 9.7%90 mg NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 6.1%De Novo Participants NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 4.3%180 mg subcutaneous NCT03978832 · Phase 4 · registry result, not featured evidence 6.7%120 mg NCT01677377 · Phase 2 · registry result, not featured evidence 0%90 mg NCT01677377 · Phase 2 · registry result, not featured evidence 0%60 mg NCT01677377 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 5 mg twice dailya daytime drowsiness 22.2% NCT01549041 · Phase 4 · registry result, not featured evidence show 19 more results10 mg daily in the evening daytime drowsiness 0% NCT01549041 · Phase 4 · registry result, not featured evidence 5/10 mg BID nasopharyngitis 21.7% schizophrenia 10.8% somnolence 10.8% NCT01142596 · Phase 3 · registry result, not featured evidence 5 mg BID insomnia 15% (placebo 13.9%) headache 8.8% (placebo 2%) anxiety 7.1% (placebo 11.9%) NCT01617187 · Phase 3 · registry result, not featured evidence 2.5 mg BID headache 10.3% (placebo 2%) insomnia 9.3% (placebo 13.9%) anxiety 7.2% (placebo 11.9%) NCT01617187 · Phase 3 · registry result, not featured evidence nasopharyngitis 21% somnolence 12.7% weight increased 12.7% NCT01244828 · Phase 3 · registry result, not featured evidence 5 mg BID akathisia 11.4% (placebo 5.2%) hypoaesthesia oral 10.9% (placebo 3.4%) insomnia 9.7% (placebo 12.1%) NCT01098110 · Phase 3 · registry result, not featured evidence 10 mg BID schizophrenia 13.8% (placebo 24.1%) somnolence 12.2% (placebo 1.7%) akathisia 10.5% (placebo 5.2%) NCT01098110 · Phase 3 · registry result, not featured evidence accidental overdose 12.5% acne 12.5% akathisia 12.5% NCT01190267 · Phase 3 · registry result, not featured evidence somnolence 14.8% headache 6.6% sedation 5.1% NCT01190267 · Phase 3 · registry result, not featured evidence 5.0 mg BID somnolence 17% (placebo 6.9%) sedation 11.3% (placebo 2%) insomnia 9.4% (placebo 5.9%) NCT01190254 · Phase 3 · registry result, not featured evidence 2.5 mg BID somnolence 20.4% (placebo 6.9%) dizziness 7.1% (placebo 1%) headache 7.1% (placebo 5.9%) NCT01190254 · Phase 3 · registry result, not featured evidence insomnia 10.6% weight increased 5.9% headache 2.4% NCT00174265 · Phase 3 · registry result, not featured evidence insomnia 17.6% somnolence 14.8% headache 13.5% NCT00145496 · Phase 3 · registry result, not featured evidence insomnia 20.1% (placebo 24.5%) somnolence 16% (placebo 17.2%) weight increased 14.4% (placebo 10.9%) NCT00150176 · Phase 3 · registry result, not featured evidence headache 5.2% influenza 5.2% schizophrenia 5.2% NCT00265343 · Phase 3 · registry result, not featured evidence insomnia 18.5% headache 10.9% parkinsonism 10.9% NCT00156065 · Phase 3 · registry result, not featured evidence 5 mg dystonia 66.7% dizziness 33.3% nausea 33.3% NCT01206517 · Phase 1 · registry result, not featured evidence 10 mg hypoaesthesia oral 50% dizziness 38.9% dysgeusia 38.9% NCT01206517 · Phase 1 · registry result, not featured evidence 2.5 mg sedation 33.3% dysgeusia 16.7% hypoaesthesia oral 16.7% NCT01206517 · Phase 1 · registry result, not featured evidence | 120 mgb injection site pain 22.2% (placebo 19.5%) headache 15.4% (placebo 23.7%) weight increased 12.8% (placebo 3.4%) NCT02109562 · Phase 3 · combination show 8 more results90 mg headache 17.4% (placebo 23.7%) injection site pain 15.7% (placebo 19.5%) weight increased 13% (placebo 3.4%) NCT02109562 · Phase 3 · combination 120 mg injection site pain 21.2% (placebo 7.1%) injection site induration 9.1% (placebo 0%) injection site nodule 9.1% (placebo 3.6%) NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 90 mg headache 12.9% (placebo 0%) injection site pain 12.9% (placebo 7.1%) insomnia 12.9% (placebo 3.6%) NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 weight increased 14.7% (placebo 3.6%) injection site pain 12.7% (placebo 7.1%) injection site nodule 7.1% (placebo 3.6%) NCT02203838 · Phase 3 · monotherapy · Schizophrenia · phase 3 180 mg subcutaneous upper respiratory tract infection 13% blood prolactin increased 8.7% decreased appetite 8.7% NCT03978832 · Phase 4 · registry result, not featured evidence 120 mg cough 20% dyspepsia 20% weight increased 20% NCT01677377 · Phase 2 · registry result, not featured evidence 90 mg weight increased 33.3% headache 20% dyspepsia 13.3% NCT01677377 · Phase 2 · registry result, not featured evidence 60 mg weight increased 26.7% headache 20% rash 20% NCT01677377 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Asenapine
show 1 more result
show 1 more result
show 17 more results
show 2 more results
show 19 more results
show 15 more results
show 15 more results
show 17 more results
show 17 more results
show 17 more results
show 17 more results
show 17 more results
+ 32 further endpoints in the CSV export.
Perseris
show 2 more results
show 2 more results
+ 8 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Perseris's landscape